¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Morphogenetic Protein Receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • lamellated bone
    ÃþÆÇ»À
  • lacrimal bone
    ´«¹°»À, ´©°ñ
  • long bone
    ±ä»À, Àå°ñ
  • malar bone
    ±¤´ë»À, °ü°ñ
  • marble bone disease
    ´ë¸®¼®º´, °ñÈ­¼®º´
  • maxillary bone
    À§ÅλÀ, »ó¾Ç°ñ
  • membrane bone
    ¸·»À, ¸·»ó°ñ
  • membranous bone graft
    ¸·»ÀÀ̽Ä, ¸·¼º°ñÀ̽Ä
  • metacarpal bone
    ¼ÕÇ㸮»À, Áß¼ö°ñ
  • metaplastic bone
    È­»ý»À
  • metatarsal bone
    ¹ßÇ㸮»À, ÁßÁ·°ñ
  • navicular bone
    ¹ß¹è»À, ÁÖ»ó°ñ
  • nasal bone
    ÄÚ»À, ºñ°ñ
  • nasal bone fracture
    ÄÚ»À°ñÀý
  • nonlamellated bone
    ¹«Ãþ»À
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • palatine bone
    ÀÔõÀå»À
  • parietal bone
    ¸¶·ç»À
  • pisiform bone
    Äá¾Ë»À
  • pneumatic bone
    °ø±â»À
  • premaxillary bone
    (¢¡premaxilla) ¾ÕÀ§ÅλÀ, »ó¾ÇÀü±¸°ñ
  • primary membrane bone
    ¼¼¸Á¼¶À¯¸·»À, ÀÏÂ÷¸·»À
  • pubic bone
    µÎµ¢»À, Ä¡°ñ
  • replacement bone
    (¢¡cartilage) ¿¬°ñ»À
  • reticulofibrous membrane bone
    (¢¡primary membrane bone) ¼¼¸Á¼¶À¯¸·»À, ÀÏÂ÷¸·»À
  • rudimentary bone
    ÈçÀû»À
  • scaphoid bone
    ¼Õ¹è»À
  • sesamoid bone
    Á¾ÀÚ»À
  • short bone
    ªÀº»À
  • sphenoid bone
    ³ªºñ»À
  • spongy bone
    °¹¼Ø»À, ÇØ¸é»À
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • pilus protein antigen
    ¼¶¸ð´Ü¹éÁúÇ׿ø
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • principal outer membrane protein (POMP)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • prosthetic protein
    ¹èÇÕ¼º ´Ü¹é(ÛÕùêàõÓ±ÛÜ).
  • protein
    ´Ü¹éÁú
  • protein
    ´Ü¹é(Ó±ÛÜ), ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein
    ´Ü¹é(Áú)
  • protein 3
    ´Ü¹é 3
  • protein 4.1
    ´Ü¹é 4.1
  • protein A
    ´Ü¹éÁú A (Æ÷µµ±¸±ÕÀÇ)
  • protein C
    C ´Ü¹é
  • protein score
    ´Ü¹é°¡(ËÀËÑ˧) ½ÄǰÀÇ .
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • protein index
    ´Ü¹éÁö¼ö(Ó±ÛÜò¦â¦)
  • protein kinase
    ´Ü¹éÁú Ä«À̳×ÀÌÁî
  • protein kinase c
    ´Ü¹éÄ«À̳×À̽º(´Ü¹éŰ³ªÁ¦)C(Ó±ÛÜ¡­)
  • protein losing enteropathy
    ´Ü¹é»ó½Ç¼º À庴Áõ(Ó±ÛÜßÃã÷àõíóÜ»ñø).
  • protein losing enteropathy
    ´Ü¹é»ó½Ç¼º À庴Áõ(Ó±ÛÜßÃã÷àõ íóÜ»ñø)
  • protein losing gastroenteropathy
    ´Ü¹é»ó½Ç¼º À§ÀåÁõ(¡­êÖ ñø).
  • protein losing gastroenteropathy
    ´Ü¹é»ó½Ç¼º À§ÀåÁõ(Ó±ÛÜßÃã÷àõ êÖíóñø)
  • protein malnutrition
    ´Ü¹éÁú¿µ¾çÀå¾Ö(Ó±ÛÜòõç½å×î¡äô).
  • protein malnutrition
    ´Ü¹éÁú¿µ¾çÀå¾Ö(Ó±ÛÜòõç½å×î¡äô)
  • protein metabolism
    ´Ü¹é(Áú)´ë»ç.
  • protein milk
    (°í)´Ü¹éÀ¯(ÍÔÓ±ÛÜêá).
  • protein quotient
    ´Ü¹éÁö¼ö(ËÀËÑ̤Ëà).
  • protein receptor
    ´Ü¹é¼ö¿ëü
  • protein s
    ´Ü¹éS
  • protein score
    ´Ü¹é°¡(ËÀËÑ˧) ½ÄǰÀÇ .
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • protein-calorie malnutrition
    ´Ü¹éÁú(Ó±ÛÜòõ)-Ä®·Î¸® ¿µ¾ç½ÇÁ¶(ç½å×ã÷ðà)
  • protein coat
    ´Ü¹éÁú(Ó±ÛÜòõ) ÄÚÆ®
  • protein conformation
    ´Ü¹éÁú(Ó±ÛÜòõ) ÀÔüÇüÅÂ(Ø¡ô÷û¡÷¾)
  • protein domain
    ´Ü¹éÁú ¿µ¿ª(Ó±ÛÜòõÖÅæ´)
  • protein efficiency ratio
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ(üù×ËÝï)
  • protein efficiency ratio method
    ´Ü¹éÁú(Ó±ÛÜòõ) È¿À²ºñ¹ý(üù×ËÝïÛö)
  • protein engineering
    ´Ü¹éÁú °ø¹ý(Ó±ÛÜòõÍïÛö)
  • protein error
    ´Ü¹éÁú ¿ÀÂ÷(Ó±ÛÜòõè¦ó¬)
  • protein evolution
    ´Ü¹éÁú ÁøÈ­(Ó±ÛÜòõòäûù)
  • protein export
    ´Ü¹éÁú À¯Ãâ(Ó±ÛÜòõ×µõó)
  • protein factor
    ´Ü¹éÁú ÀÎÀÚ(Ó±ÛÜòõì×í­)
  • protein folding
    ´Ü¹éÁú(Ó±ÛÜòõ) Á¢±â
  • protein fractionation
    ´Ü¹éÁú ºÐȹȭ(Ó±ÛÜòõÝÂüñûù)
  • protein free filtrate
    Á¦(ð¶)´Ü¹éÁú ¿©°ú¾×(Ó±ÛÜòõÕëΦäû)
  • protein import
    ´Ü¹éÁú À¯ÀÔ(Ó±ÛÜòõ×µìý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
BML bone marrow lymphocytosis
BMN bone marrow necrosis
BMT Bachelor of Medical Technology; basement membrane thickening; benign mesenchymal tumor; bone marrow ...
BRA bilateral renal agenesis; bone-resorbing activity; brain-reactive antibody
BRF bone-resorbing factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
BGP Bone GLA protein
BMP Bone Morphogenic Protein
ABD Adynamic Bone Disease
AlloBMT Allogeneic Bone Marrow Transplantation
ABMT Allogeneic bone marrow transplantation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lesser multangular bone
    ¼Ò ´Ù°¢ °ñ, ¼Ò ´ÉÇü °ñ
  • long bone
    ±ä »À, Àå°ñ
    »çÁö¿¡¼­ º¸´Â »À·Î¼­ ´ëÅð°ñ, ºñ°ñ, °æ°ñ µîÀÌ ÀÖ´Ù.
  • marble bone disease
    °ñ È­¼®Áõ, ´ë¸®¼® °ñº´
    ´ß ¹éÇ÷º´ À°Á¾±º¿¡ ¼ÓÇÏ´Â º´. °ñÇü ¸²ÇÁÁ¾À̶ó°íµµ ÇÏ´Â ÀÌ º´Àº, »À°¡ ±½¾îÁö´Â °ÍÀÌ Æ¯Â¡À̸ç, ¹ß»ýÀÌ µå¹°±â ¶§¹®¿¡ °æÁ¦ÀûÀ¸·Î Å« ¶æÀº ¾ø´Ù. Ç÷±¸¿Í ÀüÇô °ü°è¾øÀÌ »À ¼¼Æ÷°¡ Áõ½ÄÇϹǷΠÇ÷±¸¿¡¼­ À¯·¡ÇÏ´Â Á¾¾çÀÌ ¾Æ´Ï¶ó, ¹éÇ÷º´°ú °°Àº ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ÀϾ´Â º´À̱⠶§¹®¿¡ ¹éÇ÷º´À¸·Î Ãë±ÞµÈ´Ù.
  • mastoid bone
    À¯¾ç °ñ
  • maxillary bone
    »ó¾Ç°ñ
  • medullary bone
    ¼öÁú°ñ
  • metabolic bone disease
    ´ë»ç¼º °ñ Áúȯ
  • metastatic bone tumor
    ÀüÀ̼º °ñ Á¾¾ç
  • nasal bone
    ºñ°ñ
    ÄàµîÀ» Çü¼ºÇÏ´Â µÎ °³ÀÇ À广Çü »À Áß Çϳª.
  • nasal process of the frontal bone
    ÀüµÎ°ñ ºñºÎ
  • nonlamellar bone
    ºñÃþÆÇ°ñ
  • nonossified bone
    ºñ¼®È­µÈ °ñ
  • onlay bone graft
    ÁßÃþ°ñ ÀÌ½ÄÆí
    ÇÇÀ̽ÄÀÚÀÇ ÇÇÁú¼º °ñ À§¿¡ µ¤´Â ÀÌ½ÄÆíÀ¸·Î¼­ÀÇ »À.
  • palate bone
    ±¸°³°ñ
    µÎ°³°ñÀÇ Çϳª·Î »ó¾Ç°ñ°ú Á¢Çü°ñ¿¡ ³¢¾î °æ±¸°³ ÈÄºÎ¿Í ºñ°­ Ãøº® Èĺθ¦ ¸¸µé¸ç Á¿ì ÇÑ ½ÖÀÌ ÀÖ´Ù.
  • periosteal bone
    °ñ¸· °ñ, °ñ¸·¼º °ñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
receptors, peptide Cell surface receptors that bind peptide messengers with high affinity and regulate intracellular signals which influence the behaviour of cells.
(12 Dec 1998)
receptors, phencyclidine Specific sites or molecular structures on cell membranes or in cells with which phencyclidine reacts or to which it binds to elicit the specific response of the cell to phencyclidine. Studies have demonstrated the presence of multiple receptor sites for pcp. These are the pcp/sigma site, which binds both pcp and psychotomimetic opiates but not certain antipsychotics, and the pcp site, which selectively binds pcp analogs.
(12 Dec 1998)
receptors, pituitary hormone Cell surface proteins that bind pituitary hormones with high affinity and trigger intracellular changes influencing the behaviour of cells. Since many pituitary hormones are also released by neurons as neurotransmitters, these receptors are also found in the nervous system.
(12 Dec 1998)
receptors, pituitary hormone-regulating hormone Cell surface receptors that bind the hypothalamic hormones regulating pituitary cell differentiation, proliferation, and hormone synthesis and release, including the pituitary-releasing and release-inhibiting hormones. The pituitary hormone-regulating hormones are also released by cells other than hypothalamic neurons, and their receptors also occur on non-pituitary cells, especially brain neurons, where their role is less well understood. Receptors for dopamine, which is a prolactin release-inhibiting hormone as well as a common neurotransmitter, are not included here.
(12 Dec 1998)
receptors, platelet-derived growth factor Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain.
(12 Dec 1998)
receptors, polymeric immunoglobulin Specialised fc receptors (receptors, fc) for polymeric immunoglobulins, which mediate transcytosis of polymeric IgA and IgM into external secretions. They are found on the surfaces of epithelial cells and hepatocytes. After binding to IgA, the receptor-ligand complex undergoes endocytosis, transport by vesicle, and secretion into the lumen by exocytosis. Before release, the part of the receptor (secretory component) that is bound to IgA is proteolytically cleaved from its transmembrane tail.
(12 Dec 1998)
receptors, presynaptic Neurotransmitter receptors located on or near presynaptic terminals or varicosities. Presynaptic receptors which bind transmitter molecules released by the terminal itself are termed autoreceptors.
(12 Dec 1998)
receptors, progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, a and b. Both are induced by oestrogen and have short half-lives.
(12 Dec 1998)
receptors, prolactin Labile proteins on or in prolactin-sensitive cells that bind prolactin initiating the cells' physiological response to that hormone. Mammary casein synthesis is one of the responses. The receptors are also found in placenta, liver, testes, kidneys, ovaries, and other organs and bind and respond to certain other hormones and their analogs and antagonists. This receptor is related to the growth hormone receptor.
(12 Dec 1998)
receptors, prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin d2 (dp receptors), prostaglandin e2 (ep1, ep2, and ep3 receptors), prostaglandin f2-alpha (fp receptors), and prostacyclin (ip receptors).
(12 Dec 1998)
receptors, prostaglandin e Cell surface receptors which bind prostaglandins with a high affinity and trigger intracellular changes which influence the behaviour of cells. Prostaglandin e receptors prefer prostaglandin e2 to other endogenous prostaglandins. They are subdivided into ep1, ep2, and ep3 types based on their effects and their pharmacology.
(12 Dec 1998)
receptors, purinergic Cell surface proteins that bind purines with high affinity and trigger intracellular changes which influence the behaviour of cells. The best characterised classes of purinergic receptors in mammals are the p1 receptors, which prefer adenosine, and the p2 receptors, which prefer ATP or ADP.
(12 Dec 1998)
receptors, purinergic p1 A class of cell surface receptors that prefers adenosine to other endogenous purines. Purinergic p1 receptors are widespread in the body including the cardiovascular, respiratory, immune, and nervous systems. There are at least two pharmacologically distinguishable types (a1 and a2, or ri and ra). The methylxanthines, e.g., caffeine, bind to these receptors, but also have other unrelated effects.
(12 Dec 1998)
receptors, purinergic p2 A class of cell surface receptors for purines that prefer ATP or ADP over adenosine. P2 purinergic receptors are widespread in the periphery and in the central and peripheral nervous system. Subtypes have been proposed, usually designated p2 x, y, z, and t. P2x receptors may mediate fast synaptic transmission by ATP. The ADP-preferring p2t receptors in platelets stimulate aggregation.
(12 Dec 1998)
receptors, retinoic acid Proteins in the nucleus or cytoplasm that specifically bind retinoic acid or retinol and trigger changes in the behaviour of cells. Retinoic acid receptors, like steroid receptors, are ligand-activated transcription regulators. Several types have been recognised.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á